Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan

BACKGROUND: Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for refractory metastatic colorectal cancer (mCRC). No results of large real-world data directly comparing FTD/TPI + bevacizumab (BEV) with FTD/TPI or REG monotherapy have been reported. We evaluated the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Kagawa, Y., Shinozaki, E., Okude, R., Tone, T., Kunitomi, Y., Nakashima, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515287/
https://www.ncbi.nlm.nih.gov/pubmed/37562196
http://dx.doi.org/10.1016/j.esmoop.2023.101614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515287/
https://www.ncbi.nlm.nih.gov/pubmed/37562196
http://dx.doi.org/10.1016/j.esmoop.2023.101614

Ejemplares similares